St-georges De Beauce, Canada
- Featured
We are currently recruiting participants for the BLUEPRINT study. This study investigates the effectiveness, safety, and tolerability of the drug BLU-5937 for chronic itch in people with eczema.
For more information and to register to the study, please visit the study page: **<https://innovaderm.com/studies/blueprint-study-atopic-dermatitis/>**
Phase
2Span
Sponsor
Montreal, Quebec
Recruiting
- Featured
The Canadian Open Parkinson Network
Becoming a C-OPN participant involves completing online questionnaires and 1 in-person visit. There are 3 key components: 1) C-OPN Database * Answer questions about yourself and your lifestyle, medical history, family history, current medications, and other symptoms you may or may not experience. * This can be done either online, or over the phone or in-person with a C-OPN Coordinator. * Information is also gathered from cognitive testing (MoCA) and motor assessment (MDS-UPDRS), both of which are done during the 1 in-person visit with a C-OPN Coordinator at one of the C-OPN Sites listed above. * All information stored in the database is de-identified (meaning removal of any person information). 2) C-OPN Biobank * Participants can choose to donate a blood sample, which would be drawn during the 1 in-person visit with a C-OPN Coordinator at one of the C-OPN Sites listed above. * Blood samples are processed into DNA, serum, and peripheral blood mononuclear cells (PBMC), and stored in Montreal, Quebec. * All blood samples stored in the biobank are de-identified (meaning removal of any person information). 3) C-OPN Registry * Participants can choose to be part of the C-OPN Registry, in which they opt to receive e-mail notifications about upcoming research studies looking to recruit participants. We ask that participants enroll for a period of at least three years so that the C-OPN team can gather information on disease development and progression, as well as natural aging. Follow-up involves completing two questionnaires, either online or over the phone with the Site Coordinator, every 18 months. There is no in-person visit involved in the follow-up.
Phase
N/ASpan
292 weeksSponsor
Parkinson Canada and Brain Canada -- Funding for C-OPN was made possible by the Canada Brain Research Fund, an innovative arrangement between the Government of Canada (through Health Canada) and Brain Canada Foundation, and Parkinson Canada.Montréal, Quebec
Recruiting
Healthy Volunteers
- Featured
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease (REASON)
Phase
1Span
225 weeksSponsor
BiogenMontreal, Quebec
Recruiting
- Featured
We are currently recruiting patients with Palmoplantar Pustulosis (PPP). This study investigates the Efficacy and safety of ANB019.
Visit our website for more information: [_**www.pustulardermstudies.com**_](https://ppp.pustulardermstudies.com/patient/qualify/?media_label=centerwatch)
Phase
2Span
Sponsor
Montreal, Quebec
Recruiting
- Featured
Integument-1 study
The study drug consists of a cream of the medication or a placebo (same cream without the active drug) that will be applied once daily for 28 days. This treatment is experimental, and you (or your child) will have 1 in 2 chances to be part of the placebo part of the study. At the end of the study, participants may be eligible to participate in the open-labeled study, which would allow the participants to continue to receive the study treatment. More information will be made available to the participants should they be interested. Blood samples will be collected on screening, day 1 and week 4. If you consent to medical photography, it will be performed at day 1, week 1 and week 4. For more information and to register to the study, please visit the study page: http://eczema-study.com/
Phase
3Span
Sponsor
ArcutisMontreal, QC
Recruiting
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
Phase
1/2Span
150 weeksSponsor
Vertex Pharmaceuticals IncorporatedMont-Royal
Recruiting
A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions
This is a single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover study design, in which 32 healthy adult subjects received one of the study treatments during each study period. The objective of this study is to determine the bioequivalence of two different formulations of olmesartan medoxomil/ HCTZ after a single oral dose administration under fasting conditions. The intra-subject variation following a single dose of olmesartan/ HCTZ appears to be around 25% for Cmax and around 18% for AUC0-T for olmesartan and around 18% for Cmax and around 13% for AUC0-T for HCTZ. Statistically, given that the expected Test to Reference ratio of geometric LSmeans should fall within 95 and 105%, it is estimated that the lowest number of subjects to meet the 80 to 125% bioequivalence range for each analyte with a statistical a priori power of at least 80% is about 28. Therefore, the inclusion of 32 subjects should be sufficient to account for the possibility of drop-outs, variations around the estimated intra-subject CV and to conclude in favor of the hypothesis of bioequivalence with sufficient statistical power. A Caucasian population will be enrolled to minimize variability and optimize detection of differences between the Test and Reference formulations without regard to race. Subject eligibility for this study will be determined at the screening visit and eligible subjects will be admitted to the clinical research unit at least 10 hours prior to drug administration for each study period. Standbys should be recruited and available to replace any subject who withdraws prior to the first drug administration. On-study drop-outs will not be replaced. Altasciences will generate the randomization code with a computer program according to the study design, the number of subjects and the sequence of treatment administration. The random allocation of each sequence of treatment administration to each subject will be done in such a way that the study is balanced. Once generated, the randomization code will be final and will not be modified. Eligible subjects will be randomized to one of two treatment sequences. There will be two sequences in the study: AB and BA, where A = the test product, B = the reference product (see detailed description of A and B items in Section "Arms and Interventions"). For each study period, subjects will receive a single 40 mg/25 mg oral dose of olmesartan medoxomil/HCTZ, under fasting conditions and undergo a 48-hour PK sample collection. Study participants will be aware they will receive different formulations of the same drug, without being informed which product (Test or Reference) is being administered. The date and time of each dose will be recorded. For each subject, all scheduled postdose activities and assessments will be performed relative to the time of study drug administration. Subjects will fast overnight (no food or drink except water), for a minimum of 10 hours prior to dosing. Fasting will continue for at least 4 hours following drug administration, after which a standardized lunch will be served. A supper and a light snack will be served at appropriate times thereafter, but not before 9 hours after dosing. Water will be provided as needed until 1 hour predose. Water will be allowed beginning 1 hour after the administration of the drug. A total of 42 blood samples will be collected (1 tube of 3 mL for olmesartan and 1 tube of 3 mL for HCTZ at each time point) in each study period for PK assessments. The first blood sample will be collected prior to drug administration while the others will be collected up to 48 hours after drug administration. Given that olmesartan medoxomil is rapidly and completely converted to the pharmacologically active metabolite, olmesartan, and that no intact olmesartan medoxomil or intact side chain medoxomil moiety have been detected in plasma1,2, olmesartan medoxomil cannot be reliably measured. Therefore, the analytes to be measured in the study will be olmesartan and hydrochlorothiazide. Olmesatran and HCTZ plasma concentrations will be measured according to validated bioanalytical methods. Subjects are to be discharged from the clinic after the 24-hour postdose PK sample collection, and following medical approval. However, they may be advised to stay at the clinical site for safety reasons, if judged necessary by the physician in charge. Subjects will return to the clinic for blood collections at 48 hours postdose. The expected terminal half-life values observed after a single oral 40 mg/25 mg dose of olmesartan medoxomil/HCTZ film-coated tablet under fasting conditions are 8.6 hours for olmesartan and 10.3 hours for HCTZ. To avoid any carry-over effect, a wash-out of 7 calendar days is planned between drug administrations, corresponding to more than 16 times the expected half-life of the moieties to be measured. The decision of which subjects will be included in the PK analysis is to be documented by the pharmacokineticist (or delegate) and approved by the sponsor before the start of the sample analysis by the bioanalytical facility. Subjects who are expected to provide evaluable PK data for both the Test and Reference products (based on viable PK samples) will be included in the pharmacokinetic analysis. Concentration data of the remaining subjects will be presented separately. Subjects who do not complete the sampling schedule of one or more study periods may be included in the PK and statistical analysis and bioequivalence determination for only the PK parameters that are judged not to be affected by the missing sample(s). Statistical analysis of Tmax will be based on a non-parametric approach. Statistical analysis of all other PK parameters will be based on an Analysis of Variance (ANOVA) model. Two-sided 90% confidence interval of the ratio of geometric Least-Square means (LSmeans) obtained from the ln transformed PK parameters will be calculated. Statistical inference of olmesartan and HCTZ will be based on a bioequivalence approach using the following standards: the ratio of geometric LSmeans with corresponding 90% confidence interval calculated from the exponential of the difference between the Test and the Reference for the ln-transformed parameters Cmax and AUC0-T should all be within the 80.00 to 125.00% bioequivalence range. The safety population will include all subjects who received at least one dose of one of the IPs. Safety assessments will include vital signs, clinical laboratory tests, and AE monitoring. Additional safety measurements may be performed at the discretion of the investigator for reasons related to subject safety. The physician in charge will be present at the clinical site for at least the first 4 hours following each drug administration and will remain available at all times throughout the study. Total study duration: up to 38 days (including screening).
Phase
1Span
8 weeksSponsor
Pharmtechnology LLCMont-Royal, Quebec
Recruiting
Healthy Volunteers